Journal of Antimicrobial Chemotherapy (1999) 44, 429-437
© 1999 The British Society for Antimicrobial Chemotherapy
Review |
The use of fluconazole and itraconazole in the treatment of Candida albicans infections: a review
Department of Clinical Dental Sciences, University of Liverpool, Liverpool L69 3BX, UK
Candida albicans is responsible for most fungal infections in humans. Fluconazole is well established as a first-line management option for the treatment and prophylaxis of localized and systemic C. albicans infections. Fluconazole exhibits predictable pharmacokinetics and is effective, well tolerated and suitable for use in most patients with C. albicans infections, including children, the elderly and those with impaired immunity. Prophylactic administration of fluconazole can help to prevent fungal infections in patients receiving cytotoxic cancer therapy. The increasing use of fluconazole for the long-term prophylaxis and treatment of recurrent oral candidosis in AIDS patients has led to the emergence of C. albicansinfections that are not responsive to conventional doses. Second-line therapy with a wider spectrum antifungal, such as itraconazole, should be sought if treatment with fluconazole fails. A solution formulation of itraconazole has recently been introduced to overcome the poor and variable absorption of its original capsule formulation. Efficacy and tolerability studies in HIV-positive or immunocompromised patients with C. albicans infections have shown that, although itraconazole solution is as effective as fluconazole, it is less well tolerated as first-line therapy. Itraconazole solution can be effective in AIDS patients with C. albicansinfections that are non-responsive to fluconazole. No efficacy or tolerability data are available on the use of itraconazole solution in children or the elderly.
* Tel:+44-151-706-5266; Fax: +44-151-706-5809; E-mail: mvmartin{at}liverpool.ac.uk
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N Somchit, A R Norshahida, A H Hasiah, A Zuraini, M R Sulaiman, and M M Noordin Hepatotoxicity induced by antifungal drugs itraconazole and fluconazole in rats: a comparative in vivo study Human and Experimental Toxicology, November 1, 2004; 23(11): 519 - 525. [Abstract] [PDF]
|
|
|
|
 |
|
 K. Niimi, D. R. K. Harding, R. Parshot, A. King, D. J. Lun, A. Decottignies, M. Niimi, S. Lin, R. D. Cannon, A. Goffeau, et al. Chemosensitization of Fluconazole Resistance in Saccharomyces cerevisiae and Pathogenic Fungi by a D-Octapeptide Derivative Antimicrob. Agents Chemother., April 1, 2004; 48(4): 1256 - 1271. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hirasawa and K. Takada Multiple effects of green tea catechin on the antifungal activity of antimycotics against Candida albicans J. Antimicrob. Chemother., February 1, 2004; 53(2): 225 - 229. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Rubio, J. Gil, I. R. de Ocariz, R. Benito, and A. Rezusta Comparison of Results Obtained by Testing with Three Different Agar Media and by the NCCLS M27-A Method for In Vitro Testing of Fluconazole against Candida spp. J. Clin. Microbiol., June 1, 2003; 41(6): 2665 - 2668. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-L. Pagani, J.-P. Chave, C. Casjka, M.-P. Glauser, and J. Bille Efficacy, tolerability and development of resistance in HIV-positive patients treated with fluconazole for secondary prevention of oropharyngeal candidiasis: a randomized, double-blind, placebo-controlled trial J. Antimicrob. Chemother., August 1, 2002; 50(2): 231 - 240. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Zaragoza, C. de Virgilio, J. Ponton, and C. Gancedo Disruption in Candida albicans of the TPS2 gene encoding trehalose-6-phosphate phosphatase affects cell integrity and decreases infectivity Microbiology, May 1, 2002; 148(5): 1281 - 1290. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Kronvall and I. Karlsson Fluconazole and Voriconazole Multidisk Testing of Candida Species for Disk Test Calibration and MIC Estimation J. Clin. Microbiol., April 1, 2001; 39(4): 1422 - 1428. [Abstract] [Full Text]
|
|